Is Organon’s acquisition good for women’s health - or just good business?

What's next now Sun Pharma has acquired Organon?

When Organon was spun out of Merck & Co. in 2021, it stood out as one of the few scaled pharmaceutical companies built explicitly around women’s health.

That was especially important in a market where only a small share of biopharma R&D is directed toward female-specific conditions. To many working in women’s health, Organon has felt like a posterchild for the industry - a rare attempt to build a global women’s health platform.

Now, that platform is being acquired by Sun Pharmaceutical Industries.

So is this good for Organon - and is it good for women’s health more broadly?